证券代码：688301 证券简称：奕瑞科技 转债代码：118025 转债简称：奕瑞转债 （修订稿） 二〇二四年八月 1 上海奕瑞光电子科技股份有限公司（以下简称"奕瑞科技"或"公司"）为上海 证券交易所科创板上市公司。为满足公司经营战略实施和业务发展的资金需求，增强 公司的资本实力和盈利能力，根据《中华人民共和国公司法》《中华人民共和国证券 法》和《上市公司证券发行注册管理办法》（以下简称"《注册管理办法》"）等有 关法律、行政法规、部门规章、规范性文件和《公司章程》的规定，公司编制了 2024 年度向特定对象发行 A 股股票发行方案论证分析报告。 上海奕瑞光电子科技股份有限公司 iRay Technology Company Limited （上海市浦东新区瑞庆路 590 号 9 幢 2 层 202 室） 2024 年度向特定对象发行 A 股股票 方案论证分析报告 本论证分析报告中如无特别说明，相关用语具有与《上海奕瑞光电子科技股份有 限公司 2024 年度向特定对象发行 A 股股票预案（修订稿）》中相同的含义。 一、本次发行的背景和目的 （一）本次发行的背景 1、国家政策鼓励重点突破 X 线影像设备及其核 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of RMB 1.5 billion for the fiscal year, representing a 20% year-over-year growth[15]. - The company's operating revenue for 2023 was CNY 1,863,788,559.93, representing a 20.31% increase compared to CNY 1,549,116,657.78 in 2022[23]. - The net profit attributable to shareholders for 2023 was CNY 607,497,288.52, a decrease of 5.27% from CNY 641,300,445.36 in 2022[23]. - The net profit after deducting non-recurring gains and losses was CNY 591,345,651.53, which is a 14.43% increase from CNY 516,793,469.55 in 2022[23]. - The company reported a net profit of CNY 136,722,692.11 in Q1 2023, with a total operating revenue of CNY 440,366,786.18 for the same quarter[26]. - The company achieved operating revenue of 1.864 billion yuan, representing a year-on-year growth of 20.31%[36]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion CNY for the fiscal year, representing a 15% year-over-year growth[169]. - The company reported a significant increase in revenue for 2023, with a year-over-year growth of 25%[176]. Dividends and Share Capital - The company plans to distribute a cash dividend of 20 CNY per 10 shares, totaling approximately 203.65 million CNY, which represents 33.52% of the net profit attributable to ordinary shareholders[5]. - The company intends to increase its share capital by 4 shares for every 10 shares held, resulting in an increase of approximately 40.73 million shares, raising the total share capital to about 142.73 million shares[5]. - The total cash dividend amount, including the repurchase of shares, is 223,628,503.87 RMB, accounting for 36.81% of the net profit attributable to ordinary shareholders in the consolidated financial statements[200]. Research and Development - The company has invested RMB 200 million in R&D for new technologies, aiming to innovate in the field of medical imaging and diagnostics[15]. - The total R&D investment for the year reached approximately ¥262.68 million, representing a 10.02% increase from the previous year, with R&D expenses accounting for 14.09% of operating revenue[90]. - The company has filed 62 new intellectual property applications during the reporting period, including 32 invention patent applications, and has received 76 new IP registrations or authorizations[87]. - The company has developed a complete technology system for TFT sensor design, achieving 36 integrated circuit layout design registration certificates, enhancing its innovation capabilities compared to competitors[72]. - The company is investing heavily in R&D, with a budget increase of 30% to 150 million for new technologies[174]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in market share within the next two years[15]. - The company is actively exploring upstream components and raw materials for detectors, having completed the R&D of 2D collimators for medical CT and entered mass production[43]. - The company aims to deepen strategic partnerships with major clients and expand into new markets, focusing on customer needs and potential growth points[151]. - The company is considering mergers and acquisitions to integrate advanced technologies and strengthen its competitive position in the digital X-ray imaging sector[154]. - The company is exploring potential acquisitions to enhance its product portfolio, targeting firms with a combined revenue of 500 million[174]. Governance and Compliance - The company has received a standard unqualified audit report from its accounting firm, ensuring the accuracy and completeness of the financial report[4]. - The company has confirmed that all board members attended the board meeting, ensuring governance compliance[4]. - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective decision-making and operational standards[156]. - The company held four shareholder meetings during the reporting period, with all proposals approved and no proposals rejected[160]. - The company has implemented a responsibility insurance plan for directors and senior management, enhancing governance and risk management[160]. Risks and Challenges - The company has outlined potential risks in its management discussion and analysis section, emphasizing the importance of investor awareness regarding these risks[3]. - The company faces risks related to intellectual property protection and potential technology leaks, which could negatively impact its competitive edge and operational performance[102]. - There is a risk of falling behind in technology and product development if the company fails to adapt to revolutionary new technologies in its industry[103]. - The company relies on a concentrated supply chain for key raw materials, with over 20% sourced internationally, which poses risks if suppliers fail to deliver[105]. - The company is at risk of losing key personnel, which could lead to technology leaks and hinder new product and market development[108]. Employee and Management - The company has a total of 1,661 employees, reflecting a year-on-year increase of 34.28%, with R&D personnel numbering 514, up 25.98%[39]. - The total remuneration for core technical personnel at the end of the reporting period was CNY 6.875 million[177]. - The company has a diverse educational background among its employees, with 30 holding doctoral degrees and 205 holding master's degrees[193]. - The company appointed new deputy general managers during the year, indicating a potential shift in management structure[178]. Product Development and Innovation - New product development includes advancements in digital X-ray detectors, with a focus on flat panel and linear detectors, expected to enhance imaging quality in medical diagnostics[15]. - The company has successfully developed and entered mass production of new core components, including micro-focus closed ray tubes at 90kV, 130kV, and 150kV, breaking the import monopoly in this field[34]. - The company has launched several new products, including the first flexible wireless industrial detector NDT 1717BA and the high-end DSA CMOS detector Pluto 1216X, contributing over 415 million RMB in revenue from products utilizing new sensor technologies[34]. - The company has developed multiple X-ray integrated solution products for various fields and has begun small-batch deliveries to customers[43]. - The company has successfully developed a high-performance readout chip for digital X-ray detectors, achieving commercial mass production and reaching international product standards[76].

重要内容提示： 因上海奕瑞光电子科技股份有限公司（以下简称"公司"）实施 2023 年年度 权益分派、可转债转股以及股权激励限制性股票归属事项，公司总股本发生变化， 故公司 2024 年度向特定对象发行 A 股股票的发行数量上限由不超过 15,299,839 股（含本数）调整为不超过 21,418,292 股（含本数）。 一、本次向特定对象发行 A 股股票事项情况 公司于 2024 年 4 月 28 日召开第三届董事会第四次会议以及第三届监事会 第四次会议，于 2024 年 5 月 24 日召开 2023 年年度股东大会，会议审议通过了 《关于公司 2024 年度向特定对象发行 A 股股票方案的议案》等议案，具体内容 详见公司在上海证券交易所网站（www.sse.com.cn）上披露的《上海奕瑞光电子 科技股份有限公司 2024 年度向特定对象发行 A 股股票预案》等相关文件。本次 向特定对象发行 A 股股票关于发行数量的情况如下： | 证券代码：688301 | 证券简称：奕瑞科技 公告编号：2024-047 | | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | 本次发行的 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥490,911,525.92, representing an increase of 11.48% compared to the same period last year[4] - The net profit attributable to shareholders for Q1 2024 was ¥139,287,790.89, reflecting a growth of 1.88% year-over-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥155,573,268.23, which is an increase of 6.00% compared to the previous year[4] - Total operating revenue for Q1 2024 reached ¥490,911,525.92, an increase of 11.9% compared to ¥440,366,786.18 in Q1 2023[18] - Net profit for Q1 2024 was ¥154,110,203.91, slightly up from ¥148,319,046.72 in Q1 2023[18] - The total profit for Q1 2024 is approximately ¥154.16 million, compared to ¥148.71 million in Q1 2023, reflecting an increase of about 3.0%[19] - The net profit for Q1 2024 is approximately ¥137.16 million, up from ¥134.98 million in Q1 2023, representing a growth of about 1.6%[19] - The total comprehensive income for Q1 2024 is approximately ¥135.10 million, compared to ¥131.91 million in Q1 2023, reflecting an increase of about 2.7%[19] Research and Development - The total R&D investment for Q1 2024 amounted to ¥68,541,759.76, accounting for 13.96% of operating revenue, an increase of 0.9 percentage points year-over-year[5] - Research and development expenses increased to ¥68,541,759.76 in Q1 2024, compared to ¥57,527,080.59 in Q1 2023, reflecting a growth of 19.1%[18] Assets and Liabilities - The company's total assets at the end of Q1 2024 were ¥8,081,355,865.21, up 7.59% from the end of the previous year[5] - Total assets as of Q1 2024 amounted to ¥8,081,355,865.21, an increase from ¥7,511,348,212.00 in the previous year[16] - Total liabilities for Q1 2024 were ¥3,583,352,371.48, compared to ¥3,158,323,975.51 in Q1 2023, marking an increase of 13.4%[16] - Current assets totaled ¥4,007,240,874.97 in Q1 2024, up from ¥3,717,161,628.97 in Q1 2023[16] - Non-current assets reached ¥4,074,114,990.24 in Q1 2024, compared to ¥3,794,186,583.03 in Q1 2023[16] - The company's equity attributable to shareholders increased to ¥4,477,023,257.89 in Q1 2024 from ¥4,330,419,315.54 in Q1 2023[16] Cash Flow - The net cash flow from operating activities for Q1 2024 was -¥42,258,174.73, indicating a negative cash flow situation[4] - Cash inflow from operating activities in Q1 2024 is approximately ¥408.23 million, compared to ¥354.19 million in Q1 2023, showing an increase of about 15.3%[21] - Cash outflow from operating activities in Q1 2024 is approximately ¥450.49 million, compared to ¥395.26 million in Q1 2023, resulting in a net cash flow from operating activities of approximately -¥42.26 million[21] - Cash inflow from financing activities in Q1 2024 is approximately ¥1.18 billion, significantly higher than ¥2.08 million in Q1 2023[22] - The net cash flow from financing activities for Q1 2024 is approximately ¥879.85 million, compared to -¥263.49 million in Q1 2023, indicating a substantial improvement[22] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,321[9] - The diluted earnings per share for Q1 2024 was ¥1.30, a decrease of 12.07% compared to the same period last year[5] - The basic earnings per share for Q1 2024 is ¥1.37, compared to ¥1.34 in Q1 2023, indicating an increase of approximately 2.2%[19] - The total number of shares held by the top 10 unrestricted shareholders was 50,000,000, accounting for 49.02% of total shares[12] Operational Conditions - The company has not reported any significant changes in operational conditions during the reporting period[13] - The company has not disclosed any new product developments or technological advancements in this quarter[13] - There were no significant mergers or acquisitions reported during the quarter[13] Other Financial Metrics - The weighted average return on net assets for Q1 2024 was 3.17%, a decrease of 0.3 percentage points compared to the previous year[5] - The company received government subsidies amounting to ¥11,455,831.87 during the quarter, which positively impacted its financial performance[6] - The company's cash and cash equivalents amounted to approximately ¥2.01 billion, an increase from ¥1.88 billion as of December 31, 2023, representing a growth of 7%[14] - Accounts receivable increased to approximately ¥726.97 million from ¥604.59 million, reflecting a growth of 20.2%[14] - Inventory decreased slightly to approximately ¥767.29 million from ¥781.84 million, indicating a reduction of 1.9%[14] - The company’s financial assets at fair value through profit or loss decreased to approximately ¥260.21 million from ¥270.44 million, a decline of 3.5%[14] - The company’s prepayments increased to approximately ¥50.07 million from ¥29.93 million, showing a growth of 67.5%[14] Accounting Standards - The company has not applied new accounting standards for the first time in 2024[23]

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2024-046 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 上海奕瑞光电子科技股份有限公司 关于公司股东减持股份计划的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 本次减持股东持股的基本情况 截至本公告披露日，上海奕瑞光电子科技股份有限公司（以下简称"公司"、 "奕瑞科技"）股东天津红杉聚业股权投资合伙企业（有限合伙）（以下简称"天 津红杉"）、北京红杉信远股权投资中心（有限合伙）（以下简称"北京红杉"）分 别持有公司股份 10,360,832 股、4,875,775 股，分别占公司总股本的 7.26%、3.41%。 上述股份均为公司 IPO 前及上市后权益分派资本公积转增股本取得的股份，该 部分股份已于 2021 年 9 月 22 日、2023 年 4 月 24 日、2024 年 6 月 17 日上市流 通。 减持计划的主要内容 公司股东天津红杉、北京红杉拟通 ...

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2024-044 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 上海奕瑞光电子科技股份有限公司 关于"奕瑞转债"转股价格调整的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 证券代 | 证券简称 | 停复牌类型 | 停牌起始日 | 停牌 | 停牌终止 | 复牌日 | | --- | --- | --- | --- | --- | --- | --- | | 码 118025 | 奕瑞转债 | 可转债转股停 牌 | 2024/7/2 | 期间 全天 | 日 2024/7/2 | 2024/7/3 | 调整前转股价格：162.81 元/股 调整后转股价格：162.78 元/股 转股价格调整生效日期：2024 年 7 月 3 日 一、转股价格调整依据 上海奕瑞光电子科技股份有限公司（以下简称为"公司"或"奕瑞科技"）已于 近期完成了 2021 年限制性股票激励计划首次授予部分第二个 ...

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2024-043 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 上海奕瑞光电子科技股份有限公司 关于 2021 年限制性股票激励计划首次授予部分第二个 归属期第二次归属的归属结果暨股份上市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 59,682 股。 本次股票上市流通总数为 59,682 股。 本次股票上市流通日期为 2024 年 7 月 4 日。 根据中国证券监督管理委员会、上海证券交易所、中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）相关业务规定，上海奕瑞光电 子科技股份有限公司（以下简称"公司"）于近日收到中国结算上海分公司出具的《证 券变更登记证明》，公司完成了 2021 年限制性股票激励计划（以下简称"本次激励 计划"）首次授予部分第二个归属期第二次归属的股份登记工作。现将 ...

| 证券代码：688301 | 证券简称：奕瑞科技 | 公告编号：2024-045 | | --- | --- | --- | | 转债代码：118025 | 转债简称：奕瑞转债 | | 上海奕瑞光电子科技股份有限公司 关于可转债转股结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 累计转股情况：截止2024年6月30日，"奕瑞转债"累计有人民币13,274,000 元已转换为上海奕瑞光电子科技股份有限公司（以下简称 "公司"）股票，转股 数量为57,680股，占"奕瑞转债"转股前公司已发行股份总额的0.0565%； 未转股可转债情况：截止2024年6月30日，"奕瑞转债"尚未转股的可转债 金额为1,421,736,000元，占"奕瑞转债"发行总量的99.0750%； 本季度转股情况：自2024年4月1日起至2024年6月30日，"奕瑞转债"共有 人民币2,000元已转换为公司股票，转股数量为8股，占"奕瑞转债"转股前公司已 发行股份总额的0.0000%。 一、可转债发行上市概况 经中国 ...

证券代码：688301 证券简称：奕瑞科技 可转债代码：118025 可转债简称：奕瑞转债 上海奕瑞光电子科技股份有限公司 向不特定对象发行可转换公司债券 受托管理事务报告 （2023 年度） 债券受托管理人 二〇二四年六月 重要声明 本报告依据《公司债券发行与交易管理办法》（以下简称"《管理办 法》"）、《上海奕瑞光电子科技股份有限公司向不特定对象发行可转换公司 债券之债券受托管理协议》（以下简称"《受托管理协议》"）、《上海奕瑞 光电子科技股份有限公司向不特定对象发行可转换公司债券募集说明书》（以 下简称"《募集说明书》"）、《上海奕瑞光电子科技股份有限公司 2023 年年 度报告》等相关公开信息披露文件、第三方中介机构出具的专业意见等，由本 期债券受托管理人中国国际金融股份有限公司（以下简称"中金公司"）编制。 中金公司对本报告中所包含的从上述文件中引述内容和信息未进行独立验证， 也不就该等引述内容和信息的真实性、准确性和完整性做出任何保证或承担任 何责任。 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资者应对相 关事宜做出独立判断，而不应将本报告中的任何内容据以作为中金公司所作的 承诺或声明 ...

信用等级通知书 东方金诚债跟踪评字【2024】0076 号 上海奕瑞光电子科技股份有限公司： 东方金诚国际信用评估有限公司根据跟踪评级安排对贵公司及"奕 瑞转债"的信用状况进行了跟踪评级，经信用评级委员会评定，此 次跟踪评级维持贵公司主体信用等级为 AA，评级展望为稳定，同 时维持"奕瑞转债"信用等级为 AA。 东方金诚国际信用评估有限公司 信评委主任 二〇二四年六月十八日 5.本报告仅为受评对象信用状况的第三方参考意见，并非是对某种决策的结论或建议。 东方金诚不对发行人使用/引用本报告产生的任何后果承担责任，也不对任何投资者的 投资行为和投资损失承担责任。 6.本报告自出具日起生效，在受评债项的存续期内有效。其中主体评级结果有效期自 2024 年 6 月 18 日至 2025 年 6 月 17 日有效，该有效期除终止评级外，不因任何原因 调整。在评级结果有效期内，东方金诚有权作出跟踪评级、变更等级、撤销等级、中 止评级、终止评级等决定，必要时予以公布。 7.本报告的著作权等相关知识产权均归东方金诚所有。除委托评级合同约定外，委托 方、受评对象等任何使用者未经东方金诚书面授权，不得用于发行债务融资工具等证 券 ...